Bowel Cancer Screening: Who Needs What, and When — A Clear Guide to Protecting Your Colon

Bowel cancer is the second most common cause of cancer death in Australia and, at the same time, one of the most preventable cancers known to medicine. The overwhelming majority of colorectal cancers grow from small, benign polyps called adenomas over a period of ten to fifteen years. Removing those polyps before they become malignant interrupts the sequence. Detecting cancer when it is still early and localised raises five-year survival above 90%. Detecting it once it has spread drops that figure below 15%. The entire field of bowel cancer screening is built on these two facts. The question is not whether screening works — it unequivocally does — but whether the right person is being offered the right test at the right interval. This article sets out exactly that: who should be screened, with which modality, and how frequently, across every major risk category encountered in gastroenterology practice.

The Polyp-to-Cancer Sequence, in Plain Terms

Most bowel cancers arise from a normal mucosal cell that acquires a series of genetic changes, typically starting with APC mutation, proceeding through KRAS and other intermediate steps, and ending in a cell that has lost the ability to control its own growth. Along the way the cell becomes a tubular adenoma, then a larger or more dysplastic adenoma, then an invasive cancer. The journey takes on average a decade, which is why a colonoscopy performed every ten years in an average-risk adult is sufficient to keep most people permanently safe from bowel cancer. Serrated polyps, a more recently appreciated pathway, can move faster and hide more subtly on the mucosal surface, which is one reason that modern colonoscopy emphasises careful withdrawal technique, high-definition optics, and an experienced operator. Not every polyp will become cancer, but virtually every bowel cancer began as one.

Colon cancer screening at a glance: risk categories on the left, the matching screening strategy and interval on the right.

Average Risk: The Starting Point for Most Australians

An adult with no family history of bowel cancer, no personal history of polyps or inflammatory bowel disease, no concerning symptoms, and no hereditary cancer syndrome sits in the average-risk group. For this group, the National Bowel Cancer Screening Program now offers a free faecal immunochemical test — a FIT, sometimes still called FOBT — every two years from age forty-five to seventy-four. The test is simple, home-based, and quantitative: it detects human haemoglobin in stool at a threshold calibrated to pick up significant polyps and early cancers while keeping false positives manageable. A positive FIT must be followed by a colonoscopy within thirty days. A negative FIT does not exclude bowel cancer — about one in five cancers can be missed on a single FIT — which is why the programme is biennial and why persistent symptoms always warrant direct evaluation regardless of a recent negative result. For average-risk patients who prefer a definitive one-off investigation, a screening colonoscopy every ten years is an equally evidence-based alternative and is the approach I most often recommend when patients want certainty rather than surveillance.

Family History: Where Risk Starts to Climb

A family history of bowel cancer is one of the strongest non-hereditary predictors of personal risk, and the strength of that prediction depends on three things: how close the relative is, how young they were at diagnosis, and how many affected relatives there are. A single first-degree relative diagnosed at age fifty-five or older confers a modestly increased lifetime risk, and guidelines recommend colonoscopy every five years starting at age forty-five, or ten years before the age at which the relative was diagnosed, whichever comes first. A first-degree relative diagnosed under fifty, or two or more first-degree relatives with bowel cancer at any age, shifts the patient into a higher-risk group: colonoscopy every five years starting at age forty, or ten years before the youngest affected relative. Second-degree relatives matter less, but three or more affected relatives spanning two generations raises the possibility of a hereditary cancer syndrome and warrants formal genetic assessment. The principle to remember is that family history does not merely nudge the risk — in the strongest cases it doubles, triples, or quadruples it, and it changes the screening test and the starting age accordingly.

Hereditary Syndromes: The High-Stakes End of the Spectrum

Two inherited conditions dominate the hereditary colorectal cancer landscape and they require their own surveillance pathways. Lynch syndrome, caused by pathogenic variants in one of the mismatch repair genes — MLH1, MSH2, MSH6, PMS2 — carries a lifetime bowel cancer risk of up to 70 to 80 per cent and dramatically elevated risks of endometrial, gastric, urothelial, and small bowel malignancy. Affected individuals need colonoscopy every one to two years starting as young as age twenty to twenty-five, depending on the gene and the family pattern. Familial adenomatous polyposis, caused by APC mutations, leads to hundreds to thousands of colonic polyps from adolescence onwards, with a near-certain lifetime cancer risk unless surveillance and eventually prophylactic colectomy are undertaken. Recognising these syndromes early — often through family history or mismatch repair testing on an existing tumour — can save lives across generations. Any patient with a personal or strong family pattern suspicious for hereditary cancer should be referred for genetic counselling before screening is designed.

After a Polyp: Surveillance Is Not Optional

A patient who has had one or more adenomatous or serrated polyps removed at colonoscopy enters surveillance rather than screening, and the interval depends on the number, size, and histology of the polyps found. One or two small tubular adenomas under 10 mm with low-grade dysplasia warrant a repeat colonoscopy at seven to ten years in most contemporary guidelines. Three to four adenomas, or any adenoma 10 mm or larger, or any villous component, high-grade dysplasia, or advanced serrated polyp, shortens the interval to three years. Five to ten adenomas, or piecemeal removal of a large polyp, may warrant one-year surveillance. A patient told that polyps were “completely removed” is not free of future risk — the predisposition to polyp formation remains — and that is exactly why surveillance intervals exist. Missing a surveillance colonoscopy is one of the most avoidable causes of interval bowel cancer, and I see it in practice more often than I would like.

The most dangerous colonoscopy result is not a bad one. It is the good one that leads a patient to stop attending. A clear colonoscopy protects you for years, not forever — and the interval is the protection.

Inflammatory Bowel Disease: A Separate Set of Rules

Ulcerative colitis and Crohn’s colitis both raise long-term colorectal cancer risk, and the risk rises with disease duration, extent, severity of inflammation, and the presence of primary sclerosing cholangitis. For most patients with extensive colitis, surveillance colonoscopy begins eight years after symptom onset and is then repeated at one to three year intervals depending on findings, inflammation, and comorbidities. Surveillance technique matters as much as the interval: chromoendoscopy or high-definition white light with targeted biopsies, performed by an endoscopist experienced in IBD surveillance, is the standard. Patients with primary sclerosing cholangitis need annual colonoscopy from the time of diagnosis regardless of symptom duration. Colitis-associated cancer arises through a different pathway than sporadic polyp-to-cancer transformation, often via flat dysplasia that can be easy to miss on inadequate preparation or rushed withdrawal. This is one of the settings in which the person holding the colonoscope genuinely matters.

A Word on FIT, CT Colonography, and Stool DNA

Colonoscopy is the most sensitive and specific bowel cancer test available, and it is uniquely able to diagnose and treat polyps in a single session. But it is not the only tool. The faecal immunochemical test is cheap, convenient, and scalable, which is why it underpins population screening programmes. CT colonography is a reasonable alternative for patients who cannot or will not undergo colonoscopy, although it exposes patients to radiation, still requires bowel preparation, cannot remove polyps, and misses flat lesions and smaller polyps more often than colonoscopy does. Multi-target stool DNA testing, such as Cologuard, is available privately in Australia and has higher sensitivity for cancer than FIT but a higher false positive rate and a greater cost. Flexible sigmoidoscopy screens only the left colon, which in modern Australian populations misses too many right-sided cancers to be recommended as a sole screening test. Each modality has a place; none of them replaces the right colonoscopy at the right interval for the right patient.

Why a Screening Colonoscopy Is Different from a Diagnostic One

A screening colonoscopy is a test performed in an asymptomatic individual specifically to detect and remove precancerous polyps before they progress. A diagnostic colonoscopy is performed because a patient has symptoms, a positive screening test, or an abnormal investigation. The procedures look similar but the mindset is different. In a screening colonoscopy, withdrawal is slower, attention to the right colon is meticulous, retroflexion in the caecum is routine, and even the smallest polyp is considered worth removing. Quality benchmarks — caecal intubation rate above 95%, adenoma detection rate above 25% in average-risk screening populations, withdrawal time of at least six minutes — matter because they translate directly into lower rates of interval cancer. When you choose where to have a colonoscopy, the experience of the endoscopist and the quality systems of the unit genuinely affect your long-term outcome.

Symptoms That Cannot Wait for a Screening Cycle

Screening is designed for asymptomatic people. If you are bleeding per rectum, noticing a persistent change in bowel habit over weeks, passing mucus, experiencing unexplained abdominal pain or weight loss, or developing new iron deficiency anaemia, you have already moved out of the screening pathway and into the diagnostic one. These symptoms do not mean cancer — most of the time they reflect haemorrhoids, diverticular disease, IBS, or iron deficiency from other causes — but they must be evaluated promptly, and a negative FIT is not a substitute for direct visualisation. Bowel cancer is curable when caught early, and I would rather investigate ten patients whose symptoms turn out to be benign than miss the one whose do not.

When to See a Specialist

If you are approaching the age where screening begins and are unsure which modality suits you, if you have a family history of bowel cancer or polyps, if you have had polyps removed previously and are not sure when you are due for your next colonoscopy, if you live with inflammatory bowel disease, or if you are simply someone who wants certainty about your bowel health, a specialist review is worth the appointment. At Mater Private Hospital in Wollstonecraft, we provide personalised screening and surveillance programmes that take your family history, previous findings, and individual risk into account, delivered with high-definition colonoscopy in a dedicated endoscopy suite and supported by our pathology partners for polyp histology and, where indicated, mismatch repair and genetic testing. Screening is one of the few areas in medicine where a single well-timed test can change the entire trajectory of a life. If it has been ten years since your last colonoscopy — or if you have never had one and you are over forty-five — it is time to have the conversation.